Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

FDA accepts Indivior’s new drug application for schizophrenia treatment

The FTSE 250 drugmaker said the acceptance is a “significant milestone” for the treatment
depressed woman
Schizophrenia is a chronic disorder characterised by a life-long pattern of acute psychotic episodes

Indivior PLC (LON:INDV) has taken a big step towards marketing its new schizophrenia treatment in the US after the Food and Drug Administration accepted a new drug application.

On Tuesday the FTSE 250 drugmaker said it will now work closely with the FDA which it hopes will formally approve RBP-7000 – an investigational once-monthly injectable to treat the disorder – further down the line.

READ: Indivior shares surge on FDA approval for monthly treatment as US battles opioid epidemic

Results from the phase III study were released earlier this year which showed that patients’ conditions either remained stable or improved over a 12-month period.

“FDA acceptance of our RBP-7000 NDA is a significant milestone for Indivior as we expand our treatment portfolio to offer a meaningful therapeutic option to help address non-compliance with medication administration in the treatment of schizophrenia,” said chief scientific officer Christian Heidbreder.

“We look forward to closely working with the Agency during the review process to support the approval of RBP-7000 and to provide both physicians and patients this innovative treatment option.”

READ: Indivior submits new drug application to US FDA for injectable schizophrenia treatment

Earlier this month, Indivior’s experimental drug to help fight opioid addiction was approved by the FDA.

Shares rose 0.7% to 377.8p on Tuesday.

View full INDV profile View Profile

Indivior Timeline

Related Articles

picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
numerous pills
March 23 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use